Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 12
Submit an article Journal homepage
252
Views
27
CrossRef citations to date
0
Altmetric
Reviews

Recent advances in tumor vasculature targeting using liposomal drug delivery systems

Amr S Abu Lila The University of Tokushima, Institute of Health Biosciences, Department of Pharmacokinetics and Biopharmaceutics, 770-8505, Japan +81 88 633 7260; 088 633 7260; [email protected]
,
Tatsuhiro Ishida The University of Tokushima, Institute of Health Biosciences, Department of Pharmacokinetics and Biopharmaceutics, 770-8505, Japan +81 88 633 7260; 088 633 7260; [email protected]
, Phd &
Hiroshi Kiwada The University of Tokushima, Institute of Health Biosciences, Department of Pharmacokinetics and Biopharmaceutics, 770-8505, Japan +81 88 633 7260; 088 633 7260; [email protected]
, PhD
Pages 1297-1309 | Published online: 28 Sep 2009

Bibliography

  • Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7
  • Pluen A, Boucher Y, Ramanujan S, Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci USA 2001;98:4628-33
  • Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990;50(Suppl 3):814s-9s
  • Netti PA, Baxter LT, Boucher Y, Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 1995;55:5451-8
  • Tsuruo T, Tomida A. Multidrug resistance. Anticancer Drugs 1995;6:213-8
  • Peer D, Karp JM, Hong S, Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60
  • Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008;99:392-7
  • Lu Y, Yang J, Sega E. Issues related to targeted delivery of proteins and peptides. AAPS J 2006;8:E466-78
  • Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10
  • Griffioen AW, Barendsz-Janson AF, Mayo KH, Hillen HF. Angiogenesis, a target for tumor therapy. J Lab Clin Med 1998;132:363-8
  • Pezzolo A, Parodi F, Corrias MV, Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 2007;25:376-83
  • Shimizu K, Oku N. Cancer anti-angiogenic therapy. Biol Pharm Bull 2004;27:599-605
  • Ye J, Li Y, Hamasaki T, Inhibitory effect of electrolyzed reduced water on tumor angiogenesis. Biol Pharm Bull 2008;31:19-26
  • Thurston G, McLean JW, Rizen M, Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998;101:1401-13
  • Pandya NM, Dhalla NS, Santani DD. Angiogenesis–a new target for future therapy. Vascul Pharmacol 2006;44:265-74
  • Staton CA, Stribbling SM, Tazzyman S, Current methods for assaying angiogenesis in vitro and in vivo. Int J Exp Pathol 2004;85:233-48
  • Hussain S, Slevin M, Matou S, Anti-angiogenic activity of sesterterpenes; natural product inhibitors of FGF-2-induced angiogenesis. Angiogenesis 2008;11:245-56
  • Shibusa T, Shijubo N, Abe S. Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. Clin Cancer Res 1998;4:1483-7
  • Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9(Suppl 2):36-44
  • Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71
  • Fong TA, Shawver LK, Sun L, SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106
  • Kan Z, Ivancev K, Lunderquist A, In vivo microscopy of hepatic tumors in animal models: a dynamic investigation of blood supply to hepatic metastases. Radiology 1993;187:621-6
  • Stewart PA, Hayakawa K, Farrell CL, Del Maestro RF. Quantitative study of microvessel ultrastructure in human peritumoral brain tissue. Evidence for a blood-brain barrier defect. J Neurosurg 1987;67:697-705
  • Yonenaga Y, Mori A, Onodera H, Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005;69:159-66
  • Iozzo RV, San Antonio JD. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 2001;108:349-55
  • Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 2002;54:1479-84
  • Fears CY, Gladson CL, Woods A. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem 2006;281:14533-6
  • Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992;9:135-87
  • Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387-92
  • Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006;16:80-8
  • Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003;42:439-62
  • Allen TM, Brandeis E, Hansen CB, A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995;1237(2):99-108
  • Ahmad I, Longenecker M, Samuel J, Allen TM. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 1993;53:1484-8
  • Volkel T, Holig P, Merdan T, Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004;1663:158-66
  • Voinea M, Manduteanu I, Dragomir E, Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells--a potential tool for specific drug delivery. Pharm Res 2005;22:1906-17
  • Bloemen PG, Henricks PA, van Bloois L, Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett 1995;357:140-4
  • Spragg DD, Alford DR, Greferath R, Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci USA 1997;94:8795-800
  • Kessner S, Krause A, Rothe U, Bendas G. Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells. Biochim Biophys Acta 2001;1514:177-90
  • Atobe K, Ishida T, Ishida E, In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull 2007;30:972-8
  • Hatakeyama H, Akita H, Ishida E, Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 2007;342:194-200
  • Kuzu I, Bicknell R, Fletcher CD, Gatter KC. Expression of adhesion molecules on the endothelium of normal tissue vessels and vascular tumors. Lab Invest 1993;69:322-8
  • Dienst A, Grunow A, Unruh M, Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 2005;97:733-47
  • Ryan DH, Nuccie BL, Abboud CN, Winslow JM. Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. J Clin Invest 1991;88:995-1004
  • Seron D, Cameron JS, Haskard DO. Expression of VCAM-1 in the normal and diseased kidney. Nephrol Dial Transplant 1991;6:917-22
  • Bodey B, Bodey BJr, Siegel SE, Kaiser HE. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization. Anticancer Res 1998;18:3621-8
  • Dawn G, MacKie RM. Expression of endoglin in human melanocytic lesions. Clin Exp Dermatol 2002;27:153-6
  • Bendas G, Rothe U, Scherphof GL, Kamps JA. The influence of repeated injections on pharmacokinetics and biodistribution of different types of sterically stabilized immunoliposomes. Biochim Biophys Acta 2003;1609:63-70
  • Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep 2002;22(2):197-224
  • Kirpotin DB, Drummond DC, Shao Y, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732-40
  • Schiffelers RM, Koning GA, ten Hagen TL, Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003;91:115-22
  • Koning GA, Fretz MM, Woroniecka U, Targeting liposomes to tumor endothelial cells for neutron capture therapy. Appl Radiat Isot 2004;61:963-7
  • Pastorino F, Brignole C, Di Paolo D, Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66:10073-82
  • Simberg D, Duza T, Park JH, Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci USA 2007;104:932-6
  • Kondo M, Asai T, Katanasaka Y, Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004;108:301-6
  • Curnis F, Arrigoni G, Sacchi A, Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002;62:867-74
  • Pastorino F, Brignole C, Marimpietri D, Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63:7400-9
  • Oku N, Asai T, Watanabe K, Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 2002;21:2662-9
  • Maeda N, Takeuchi Y, Takada M, Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 2004;100:41-52
  • Maruyama K, Takahashi N, Tagawa T, Immunoliposomes bearing polyethyleneglycol-coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett 1997;413:177-80
  • Mislick KA, Baldeschwieler JD. Evidence for the role of proteoglycans in cation-mediated gene transfer. Proc Natl Acad Sci USA 1996;93:12349-54
  • Mounkes LC, Zhong W, Cipres-Palacin G, Proteoglycans mediate cationic liposome-DNA complex-based gene delivery in vitro and in vivo. J Biol Chem 1998;273:26164-70
  • Zuhorn IS, Kalicharan D, Robillard GT, Hoekstra D. Adhesion receptors mediate efficient non-viral gene delivery. Mol Ther 2007;15:946-53
  • Hagerstrand H, Iglic A, Bobrowska-Hagerstrand M, Amphiphile-induced vesiculation in aged hereditary spherocytosis erythrocytes indicates normal membrane stability properties under non-starving conditions. Mol Membr Biol 2001;18:221-7
  • Kitagawa S, Kasamaki M, Hyodo M. Cationic vesicles consisting of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and phosphatidylcholines and their interaction with erythrocyte membrane. Chem Pharm Bull (Tokyo) 2004;52:451-3
  • Zelphati O, Uyechi LS, Barron LG, Szoka FCJr. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta 1998;1390:119-33
  • Varsano S, Frolkis I, Ophir D. Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract. Am J Respir Crit Care Med 1995;152:1087-93
  • Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991;146:4234-41
  • Dass CR, Choong PF. Targeting of small molecule anticancer drugs to the tumour and its vasculature using cationic liposomes: lessons from gene therapy. Cancer Cell Int 2006;6:17
  • Takakura Y, Nishikawa M, Yamashita F, Hashida M. Influence of physicochemical properties on pharmacokinetics of non-viral vectors for gene delivery. J Drug Target 2002;10:99-104
  • Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul 1998;15:1-19
  • Allen C, Dos Santos N, Gallagher R, Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 2002;22:225-50
  • Song LY, Ahkong QF, Rong Q, Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta 2002;1558:1-13
  • Zalipsky S, Brandeis E, Newman MS, Woodle MC. Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett 1994;353:71-4
  • Levchenko TS, Rammohan R, Lukyanov AN, Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 2002;240:95-102
  • Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009;98:411-29
  • Campbell RB, Fukumura D, Brown EB, Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002;62:6831-6
  • Ishiwata H, Suzuki N, Ando S, Characteristics and biodistribution of cationic liposomes and their DNA complexes. J Control Release 2000;69:139-48
  • Stuart DD, Kao GY, Allen TM. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther 2000;7:466-75
  • Gabizon A. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 1995;16:285-94
  • Abu-Lila A, Suzuki T, Doi Y, Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J Control Release 2009;134:18-25
  • Harigai T, Kondo M, Isozaki M, Preferential binding of polyethylene glycol-coated liposomes containing a novel cationic lipid, TRX-20, to human subendthelial cells via chondroitin sulfate. Pharm Res 2001;18:1284-90
  • Dass CR. Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. Int J Pharm 2003;267:1-12
  • Krasnici S, Werner A, Eichhorn ME, Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003;105:561-7
  • Oikawa T, Sasaki M, Inose M, Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. Anticancer Res 1997;17:1881-6
  • Nakamura M, Katsuki Y, Shibutani Y, Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol 1999;386:33-40
  • Tagami T, Barichello JM, Kikuchi H, The gene-silencing effect of siRNA in cationic lipoplexes is enhanced by incorporating pDNA in the complex. Int J Pharm 2007;333:62-9
  • Kalra AV, Campbell RB. Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. Pharm Res 2006;23:2809-17
  • Kunstfeld R, Wickenhauser G, Michaelis U, Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a ‘humanized’ SCID mouse model. J Invest Dermatol 2003;120:476-82
  • Strieth S, Eichhorn ME, Sauer B, Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004;110:117-24
  • Schmitt-Sody M, Strieth S, Krasnici S, Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003;9:2335-41
  • Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 2007;337:329-35
  • Siim BG, Lee AE, Shalal-Zwain S, Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52
  • Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6
  • Gabizon A, Catane R, Uziely B, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92
  • Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63
  • Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006;16:175-83
  • Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 2001;7:223-5
  • Schulz G, Cheresh DA, Varki NM, Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44:5914-20
  • Abu Lila AS, Kizuki S, Doi Y, Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 2009;137:8-14
  • Ribatti D. The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des 2009;15:345-52
  • Ruegg C, Mutter N. Anti-angiogenic therapies in cancer: achievements and open questions. Bull Cancer 2007;94:753-62
  • Browder T, Butterfield CE, Kraling BM, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86
  • Klement G, Baruchel S, Rak J, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24
  • Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9
  • Huang X, Molema G, King S, Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-50
  • Maruyama K. PEG-immunoliposome. Biosci Rep 2002;22:251-66
  • Simionescu M, Simionescu N, Santoro F, Palade GE. Differentiated microdomains of the luminal plasmalemma of murine muscle capillaries: segmental variations in young and old animals. J Cell Biol 1985;100:1396-407
  • Hardebo JE, Kahrstrom J. Endothelial negative surface charge areas and blood-brain barrier function. Acta Physiol Scand 1985;125:495-9
  • Ghosh S, Maity P. Augmented antitumor effects of combination therapy with VEGF antibody and cisplatin on murine B16F10 melanoma cells. Int Immunopharmacol 2007;7:1598-608
  • Martinelli M, Bonezzi K, Riccardi E, Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007;97:888-94
  • Knox JJ, Hedley D, Oza A, Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005;23:2332-8
  • Gao D, Nolan D, McDonnell K, Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta 2009; published online 19 May 2009, doi:10.1016/j.bbcan.2009.05.001
  • Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008;28:23S-30S
  • Ding YT, Kumar S, Yu DC. The role of endothelial progenitor cells in tumour vasculogenesis. Pathobiology 2008;75:265-73

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.